Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hemorrhagic Fever Therapy
Study findings from Utah State University, Institute for Antiviral Research broaden understanding of hemorrhagic fever therapy
May 21st, 2008
Data detailed in 'Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses' have been presented. "A diverse group of highly pathogenic RNA viruses cause a severe multisystemic illness in humans commonly referred to as viral hemorrhagic fever (VHF). Although they can vary widely in clinical presentation, all VHFs share certain features that include intense fever, malaise, bleeding and shock," scientists in the United States report. "Effective antiviral therapies for most of the VHFs are lacking. Complicating development of intervention strategies is the relative infrequency and unpredictability of VHF outbreaks making human clinical trials...
Source: Vaccine Weekly (2008-05-21)
|
